Upon receipt of an atypical finding, the anti-doping organization responsible for results management shall conduct a review to determine whether: (a) an applicable tue has been granted or will be granted as provided in the international Standard for Therapeutic Use Exemptions, or (b) there is any apparent departure from the international Standard for Testing and investigations or international Standard for Laboratories that caused the atypical finding.